DUBAI, UAE, June 13, 2026 /PRNewswire/ -- Hozpitality Group successfully hosted the 9th Middle East Chef Excellence Awards 2026 alongside the 4th Middle East...
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --
-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --
SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
SHANGHAI, June 13, 2026 /CNW/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
BANGKOK, June 13, 2026 /PRNewswire/ -- Huawei Cloud Thailand has officially received a recognition for its HUAWEI CLOUD Developer Certification (HCCDX) from Thailand Professional...
New York Assemblymembers Karines Reyes andChantel Jackson Deliver Commencement AddressesBRONX, N.Y., June 12, 2026 /PRNewswire/ -- Monroe University, a national leader in educating first-generation...
FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT
Ascendus to deploy $900,000 in loans and pair every dollar with hands-on coaching, from Prospera and other partners, supporting an estimated 160 local jobs...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026...
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
BEIJING, June 12, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE: TAL), a smart learning solutions provider in China, today announced...